Publication | Open Access

The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18–59 years: A phase I randomized, double-blinded, controlled trial

VaccinologyVaccine SafetyVaccinationVaccine DevelopmentVaccine SurveillanceImmunodeficienciesImmunologyVaccine TestingVaccine EfficacyChinese AdultsInactivated Sars-cov-2 VaccineMedicineCovid-19